Screener
Sarepta Therapeutics, Inc. SRPT Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $401.25M-34.3% | $730.8M-1.9% | $442.93M— | $399.36M-14.5% | $611.09M+68.4% | ||
| $91.26M-55.4% | —— | —— | —— | $204.39M— | ||
| $107.6M-22.0% | —— | —— | —— | $137.9M— | ||
| $387.96M-21.7% | —— | —— | —— | $495.51M— | ||
| $13.29M-88.5% | —— | —— | —— | $115.58M— | ||
| 3.3%-15.6pp | —— | —— | —— | 18.9%— | ||
| -$21.51M-311% | —— | —— | —— | -$5.23M— | ||
| -$15.04M-140% | —— | —— | —— | $38.06M— | ||
| -$1.75M-101% | —— | —— | —— | $153.64M— | ||
| $3.14M+107% | —— | —— | —— | -$43.25M— | ||
| -$4.89M-102% | $330.96M+174% | -$282.85M-278% | -$179.95M-635% | $196.89M+2,948% | ||
| -1.2%-33.4pp | 45.3%+105pp | -63.9%— | -45.1%-52.3pp | 32.2%+30.4pp | ||
| -$0.05-103% | —— | —— | —— | $1.89— | ||
| $23.7M-81.3% | —— | —— | —— | $126.42M— | ||
| 5.9%-14.8pp | —— | —— | —— | 20.7%— | ||
| $13.29M-88.5% | —— | —— | —— | $115.58M— |
FAQ
- What is Sarepta Therapeutics, Inc.'s revenue?
- Sarepta Therapeutics, Inc. (SRPT) generated $2.0B in revenue over the trailing twelve months, down 9.7% year over year.
- Is Sarepta Therapeutics, Inc. profitable?
- Sarepta Therapeutics, Inc. is not currently profitable: it reported a net loss of $136.7M over the trailing twelve months, a -6.9% net margin.
- What is Sarepta Therapeutics, Inc.'s earnings per share?
- Sarepta Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.39.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
